Literature DB >> 35027991

Update on recurrent mutations in angioimmunoblastic T-cell lymphoma.

Daniel Dai Yu1, Jianzhong Zhang2.   

Abstract

Angioimmunoblastic T-cell lymphoma (AITL) is a subtype of peripheral T cell lymphoma (PTCL), defined by genetic alterations that induce abnormal immune activity and inflammatory disorders. Through recent discoveries using genomic studies, the identification of various recurrent mutations has provided greater insight and changed our understanding of the molecular genetics of the disease. By acknowledging these recurrent mutations and their affected pathways, the diagnosis, prognosis, treatment, and survival of AITL can be improved. In this review, we summarize the known recurrent mutations present in the molecular pathogenesis of AITL by emphasizing the effects of mutations on signaling pathways and genes, as well as the multistep process of AITL development. IJCEP
Copyright © 2021.

Entities:  

Keywords:  AITL; DNMT3A; IDH2; RHOA; T-cell receptor signaling; TET2

Year:  2021        PMID: 35027991      PMCID: PMC8748014     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  30 in total

1.  Recurrent activating mutations of CD28 in peripheral T-cell lymphomas.

Authors:  J Rohr; S Guo; J Huo; A Bouska; C Lachel; Y Li; P D Simone; W Zhang; Q Gong; C Wang; A Cannon; T Heavican; A Mottok; S Hung; A Rosenwald; R Gascoyne; K Fu; T C Greiner; D D Weisenburger; J M Vose; L M Staudt; W Xiao; G E O Borgstahl; S Davis; C Steidl; T McKeithan; J Iqbal; W C Chan
Journal:  Leukemia       Date:  2015-12-31       Impact factor: 11.528

2.  GAPDH Overexpression in the T Cell Lineage Promotes Angioimmunoblastic T Cell Lymphoma through an NF-κB-Dependent Mechanism.

Authors:  Laura Mondragón; Rana Mhaidly; Gian Marco De Donatis; Marie Tosolini; Pascal Dao; Anthony R Martin; Caroline Pons; Johanna Chiche; Marie Jacquin; Véronique Imbert; Emma Proïcs; Laurent Boyer; Anne Doye; Frédéric Luciano; Jaap G Neels; Frédéric Coutant; Nicole Fabien; Laura Sormani; Camila Rubio-Patiño; Jozef P Bossowski; Florian Muller; Sandrine Marchetti; Elodie Villa; Jean-François Peyron; Philippe Gaulard; François Lemonnier; Vahid Asnafi; Laurent Genestier; Rachid Benhida; Jean-Jacques Fournié; Thierry Passeron; Jean-Ehrland Ricci; Els Verhoeyen
Journal:  Cancer Cell       Date:  2019-08-22       Impact factor: 31.743

3.  Mutations in 5-methylcytosine oxidase TET2 and RhoA cooperatively disrupt T cell homeostasis.

Authors:  Shengbing Zang; Jia Li; Haiyan Yang; Hongxiang Zeng; Wei Han; Jixiang Zhang; Minjung Lee; Margie Moczygemba; Sevinj Isgandarova; Yaling Yang; Yubin Zhou; Anjana Rao; M James You; Deqiang Sun; Yun Huang
Journal:  J Clin Invest       Date:  2017-07-10       Impact factor: 14.808

4.  RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis.

Authors:  Jose R Cortes; Alberto Ambesi-Impiombato; Lucile Couronné; S Aidan Quinn; Christine S Kim; Ana C da Silva Almeida; Zachary West; Laura Belver; Marta Sanchez Martin; Laurianne Scourzic; Govind Bhagat; Olivier A Bernard; Adolfo A Ferrando; Teresa Palomero
Journal:  Cancer Cell       Date:  2018-02-02       Impact factor: 31.743

5.  IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.

Authors:  Rob A Cairns; Javeed Iqbal; François Lemonnier; Can Kucuk; Laurence de Leval; Jean-Philippe Jais; Marie Parrens; Antoine Martin; Luc Xerri; Pierre Brousset; Li Chong Chan; Wing-Chung Chan; Philippe Gaulard; Tak W Mak
Journal:  Blood       Date:  2012-01-03       Impact factor: 25.476

6.  Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas.

Authors:  Teresa Palomero; Lucile Couronné; Hossein Khiabanian; Mi-Yeon Kim; Alberto Ambesi-Impiombato; Arianne Perez-Garcia; Zachary Carpenter; Francesco Abate; Maddalena Allegretta; J Erika Haydu; Xiaoyu Jiang; Izidore S Lossos; Concha Nicolas; Milagros Balbin; Christian Bastard; Govind Bhagat; Miguel A Piris; Elias Campo; Olivier A Bernard; Raul Rabadan; Adolfo A Ferrando
Journal:  Nat Genet       Date:  2014-01-12       Impact factor: 41.307

7.  Inappropriate costimulation and aberrant DNA methylation as therapeutic targets in angioimmunoblastic T-cell lymphoma.

Authors:  Mathijs Willemsen; Harry C Schouten
Journal:  Biomark Res       Date:  2017-02-08

8.  IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma.

Authors:  Chao Wang; Timothy W McKeithan; Qiang Gong; Weiwei Zhang; Alyssa Bouska; Andreas Rosenwald; Randy D Gascoyne; Xiwei Wu; Jinhui Wang; Zahid Muhammad; Bei Jiang; Joseph Rohr; Andrew Cannon; Christian Steidl; Kai Fu; Yuping Li; Stacy Hung; Dennis D Weisenburger; Timothy C Greiner; Lynette Smith; German Ott; Eleanor G Rogan; Louis M Staudt; Julie Vose; Javeed Iqbal; Wing C Chan
Journal:  Blood       Date:  2015-08-12       Impact factor: 25.476

Review 9.  IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.

Authors:  Hui Yang; Dan Ye; Kun-Liang Guan; Yue Xiong
Journal:  Clin Cancer Res       Date:  2012-10-15       Impact factor: 13.801

10.  DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice.

Authors:  L Scourzic; L Couronné; M T Pedersen; V Della Valle; M Diop; E Mylonas; J Calvo; E Mouly; C K Lopez; N Martin; M Fontenay; A Bender; S Guibert; P Dubreuil; P Dessen; N Droin; F Pflumio; M Weber; P Gaulard; K Helin; T Mercher; O A Bernard
Journal:  Leukemia       Date:  2016-02-15       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.